Yarrow Bioscience

New Haven biotech goes public after merger, raises $200M

The newly public biotech is advancing a potential treatment for Graves' disease and thyroid eye disease, with cash expected to last into 2028.

Get our email newsletters

Stay up-to-date on the companies, people and issues that impact businesses in Hartford and beyond.

Latest Stories

CT historic preservation reforms appear to ease development concerns,...

🔒Jahana Hayes weighs House labor committee chair bid, suggests...

Sacred Heart University launches construction management degree

140-unit apartment project on former Fairfield lumberyard site moves...

More Business News

Thought Leadership

Battery Storage Is Creating a New Opportunity for Connecticut...

Trinity Health Of New England: Innovating Lung Cancer Care

More Thought Leadership

Movers & Shakers

Bob Klybas and Ray Hill have joined Weston & Sampson in their Rocky Hill office

Wooster Square Advisors Welcomes Seasoned Wealth Manager Kim Welch

Munger Construction Announce Cal Connelly as Construction Solutions Advisor

Dimeo Construction Co. Welcomes Blakely S. Dimeo as Business Development Manager

More Movers & Shakers | Submit Movers & Shakers

Business Announcements

U.S. Senator Visits Flow Tech to Discuss Employee Ownership

Essex Bank is celebrating its 175th anniversary

More Announcements | Submit Business Announcements

Upcoming Events

More Events | Submit an Event